Send to

Choose Destination
Oncotarget. 2016 Mar 29;7(13):16003-11. doi: 10.18632/oncotarget.7435.

ZEB2 inhibits HBV transcription and replication by targeting its core promoter.

Author information

Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
The Second Affiliated Hospital and The Key Laboratory of Molecular Biology of Infectious Diseases designated by The Chinese Ministry of Education, Chongqing Medical University, Chongqing, China.
Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.


Hepatitis B virus (HBV) infection is a major cause of liver diseases, especially liver cirrhosis and hepatocellular carcinoma. However, the interaction between host and HBV has not been fully elucidated. ZEB2 is a Smad-interacting, multi-zinc finger protein that acts as a transcription factor or repressor for several signaling pathways. This study found that the expression of ZEB2 was decreased in HBV-expressing cells. Overexpression of ZEB2 inhibited HBV DNA replicative intermediates, 3.5kb mRNA, core protein level, and the secretion of HBsAg and HBeAg. In contrast, ZEB2 knockdown promoted HBV replication. Furthermore, ZEB2 could bind to HBV core promoter and inhibit its promoter activity. Mutation at the ZEB2 binding site in HBV core promoter eradicated ZEB2-mediated inhibition of HBV replication. This study identifies ZEB2 as a novel host restriction factor that inhibits HBV replication in hepatocytes. These data may shed light on development of new antiviral strategies.


HBV core promoter; HBV replication; ZEB2

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center